Cachexia is muscle loss driven by an underlying illness, whereas sarcopenia is a muscle disease defined first by low muscle strength that accrues across a lifetime. At Longevity Benchmark, we see readers confuse them because both conditions erode physical function and reduce skeletal muscle mass.

A person experiencing progressive strength deficits needs a clinical evaluation focused on muscle strength, while anyone experiencing involuntary weight loss alongside chronic disease requires immediate medical workup for systemic illness.

The Verdict

Treat sarcopenia as an intrinsic muscle disease and cachexia as a metabolic syndrome driven by an underlying illness. Declining strength and involuntary weight loss are assessed under different consensus criteria, and a clinician decides which applies. Bring either change to a clinician rather than matching your own symptoms to one of these definitions.

Anyone experiencing rapid, unintentional weight loss or muscle wasting in the presence of a chronic disease must not treat their condition as simple age-related muscle loss. Stop reading general health guides and schedule an immediate clinical assessment with a physician to identify and treat the underlying illness.

What Separates Sarcopenia From Cachexia

Cachexia is muscle loss driven by an underlying illness, whereas sarcopenia is a muscle disease defined first by low muscle strength that accrues across a lifetime. The distinction between them is formal and established in clinical literature. In fact, the 2008 consensus definition of cachexia published by Evans 2008 explicitly names age-related loss of muscle mass as one of the specific entities that cachexia is distinct from.

That consensus statement establishes that cachexia is distinct from starvation, age-related loss of muscle mass, primary depression, malabsorption, and hyperthyroidism, and is associated with increased morbidity. Evans and colleagues added a qualifier: the definition has not been tested in epidemiological or intervention studies. Even with that caveat, their framework separates illness-driven metabolic wasting from the progressive structural muscle changes that occur with advancing age.

Sarcopenia received an updated definition from the European Working Group on Sarcopenia in Older People in the EWGSOP2 consensus statement. Cruz-Jentoft and colleagues define sarcopenia as a muscle disease (muscle failure) rooted in adverse muscle changes that accrue across a lifetime. EWGSOP2 notes that sarcopenia is common among adults of older age but can also occur earlier in life. While cachexia requires an underlying disease driving metabolic disruption, sarcopenia focuses squarely on the intrinsic failure of muscle tissue strength, quantity, and quality.

Clinical DimensionSarcopeniaCachexia
Consensus definition A muscle disease (muscle failure) rooted in adverse muscle changes that accrue across a lifetime A complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass
Primary biological driver Adverse muscle changes accruing across a lifetime, which can also occur earlier in life Underlying illness, inflammation, insulin resistance, and increased muscle protein breakdown
Context required Rooted in adverse muscle changes accruing across a lifetime; common in older age Associated with an underlying illness
Leading diagnostic signal Low muscle strength, assessed by functional testing and confirmed by low muscle quantity or quality Weight loss in adults (corrected for fluid retention)
Fat mass involvement Not published Characterized by loss of muscle with or without loss of fat mass
Role of conventional nutrition Not published Cancer cachexia consensus: a mainstay of therapy, though it cannot fully reverse ongoing loss
Formal staging system Graded by severity using physical performance, following case-finding, diagnosis, confirmation, and severity determination Cancer cachexia framework establishes three stages: precachexia, cachexia, and refractory cachexia
ICD-10-CM coding M62.84, housed under diseases of the musculoskeletal system and connective tissue R64, housed under general symptoms, signs, and abnormal clinical findings
Governing consensus document EWGSOP2 revised European consensus (Cruz-Jentoft 2019) Evans 2008 general consensus; Fearon 2011 for cancer cachexia

Biological Drivers and Metabolic Distinctions

Underlying metabolic drivers create the fundamental physiological divide between these two forms of muscle reduction. Sarcopenia develops through adverse muscle changes that accrue across a lifetime. These adverse muscle changes reduce muscle strength as well as muscle quantity and quality.

Cachexia operates as a complex metabolic syndrome associated with underlying illness. The Evans 2008 consensus notes that anorexia, inflammation, insulin resistance, and increased muscle protein breakdown are frequently associated with cachexia. The prominent clinical feature of cachexia is weight loss in adults, corrected for fluid retention.

Within cancer-specific research, biological mechanisms have been detailed even further. A consensus framework for cancer cachexia published by Fearon 2011 explains that cancer cachexia pathophysiology involves a negative protein and energy balance driven by a variable combination of reduced food intake and abnormal metabolism. In an international primer on cancer-associated cachexia, Baracos 2018 identifies specific tissue-level mechanisms in cancer cachexia: activation of inflammation, proteolysis, autophagy, and lipolysis. Cancer cachexia drives elevated energy expenditure, excess catabolism, and inflammation.

Diagnostic Pathways and Clinical Identification

Clinicians identify sarcopenia by testing voluntary functional strength first, whereas they detect cachexia by documenting involuntary weight loss over time. The EWGSOP2 framework for sarcopenia established an updated clinical algorithm for case-finding, diagnosis and confirmation, and severity determination. EWGSOP2 focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of low muscle quantity and quality to confirm the diagnosis, and identifies poor physical performance as indicative of severe sarcopenia.

A sarcopenia assessment therefore begins with functional physical evaluation. Clinicians screen for cases, measure muscle strength, and confirm the diagnosis by detecting low muscle quantity or quality, which can include a body-composition DEXA scan. If you want to review the clinical cut-off points and testing protocols that panels use, read our guide to sarcopenia cutpoints.

Cachexia bypasses voluntary strength testing as its entry gate and tracks weight loss instead. In the cancer cachexia consensus, Fearon and colleagues established an agreed diagnostic criterion: weight loss greater than 5 percent; or weight loss greater than 2 percent in individuals already depleted by current body-mass index (BMI under 20 kg/m2) or by skeletal muscle mass (sarcopenia). The framework also outlines four core assessment domains for cancer cachexia: anorexia or reduced food intake, catabolic drive, muscle mass and strength, and functional and psychosocial impairment. Fearon noted that after validation, this framework should aid clinical trial design, development of practice guidelines, and routine clinical management.

Nutritional Support and the Reversibility Question

The role and limits of nutritional support are explicitly defined in consensus frameworks for cachexia. For muscle recovery in sarcopenia, see our analysis of trial evidence on sarcopenia recovery.

In cancer cachexia, conventional nutritional support cannot fully reverse ongoing muscle loss. In the cancer cachexia consensus, Fearon 2011 defines cancer cachexia as a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment.

This biological barrier does not mean nutritional support should be abandoned. Baracos 2018 emphasizes that while no effective medical intervention completely reverses cancer cachexia and there are no approved drug therapies, adequate nutritional support remains a mainstay of cancer cachexia therapy. Both statements travel together in the consensus literature: medical intervention cannot completely reverse cancer cachexia, yet adequate nutritional support remains a mainstay of cancer cachexia therapy.

Malnutrition and the Unsettled GLIM Overlap

Malnutrition represents a third clinical entity that can overlap with sarcopenia and cachexia. To standardize nutritional diagnoses, the Global Leadership Initiative on Malnutrition published the GLIM criteria in a 2019 report led by Cederholm. The GLIM framework uses a two-step approach: initial screening for at-risk status with any validated screening tool, followed by formal assessment for diagnosis and severity grading.

Under GLIM, a malnutrition diagnosis requires the presence of at least one phenotypic criterion and at least one etiologic criterion. These criteria separate observable physical changes from underlying biological mechanisms:

  • Phenotypic criteria: Non-volitional weight loss, low body-mass index, and reduced muscle mass.
  • Etiologic criteria: Reduced food intake or assimilation, and disease burden or systemic inflammation.

Staging Systems and the Secondary Sarcopenia Boundary

Clinical staging protocols differ between the progressive stages of cancer cachexia and the severity grading of sarcopenia. Fearon 2011 established three distinct clinical stages for cancer cachexia: precachexia, cachexia, and refractory cachexia. Severity in cancer cachexia is classified by the degree of depletion of energy stores and body protein (assessed via BMI) combined with the degree of ongoing weight loss.

Sarcopenia staging under EWGSOP2 follows functional severity rather than weight loss increments. EWGSOP2 identifies poor physical performance as indicative of severe sarcopenia. Illness-driven muscle loss can be classified as secondary sarcopenia, as discussed on our sarcopenia diagnostic pathways page.

This creates a grey zone where the two conditions can converge. Furthermore, Baracos 2018 notes that cancer-associated cachexia is highly associated with cancers of the pancreas, oesophagus, stomach, lung, liver, and bowel, a group of malignancies responsible for half of all cancer deaths worldwide.

Clinical Codes and Who Decides Each Diagnosis

Both conditions possess dedicated diagnostic codes in the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), but they sit in entirely different chapters of medical classification. Sarcopenia carries code M62.84, classified under diseases of the musculoskeletal system and connective tissue. Cachexia carries code R64, positioned among symptoms, signs, and abnormal findings.

Neither diagnosis can be self-diagnosed or established from consumer health devices alone. Sarcopenia requires clinical assessment incorporating muscle strength testing and quantification of muscle quantity or quality by a clinician. Cachexia requires medical evaluation by a clinician to identify the underlying illness driving weight loss.

If you are monitoring changes in your physical strength or lean mass, schedule a formal clinical evaluation. You can review scheduling considerations in our guide on when to get a DEXA scan, or assess functional strength indicators on our physical biological age tests page.

Frequently Asked Questions

What is the difference between sarcopenia and cachexia?

Sarcopenia is a muscle disease defined primarily by low muscle strength and confirmed by low muscle quantity or quality, accruing across a person's lifetime. Cachexia is a complex metabolic syndrome driven by an underlying illness and characterized by loss of muscle mass with or without the loss of fat mass. The Evans 2008 consensus explicitly states that cachexia is distinct from age-related loss of muscle mass. While sarcopenia is identified through functional strength testing and detection of low muscle quantity or quality, cachexia is identified primarily through documented involuntary weight loss alongside systemic inflammation and chronic disease.

Can cachexia be reversed?

In cancer cachexia, international consensus states that ongoing muscle loss cannot be fully reversed by conventional nutritional support alone. According to the Fearon 2011 consensus framework, cancer cachexia involves abnormal metabolism and catabolic drive that ordinary feeding cannot fully overcome. A primer by Baracos 2018 confirms that no effective medical intervention completely reverses cancer cachexia and there are no approved drug therapies. However, Baracos also stresses that adequate nutritional support remains a mainstay of cancer cachexia therapy. Nutritional support therefore remains essential even though it cannot completely reverse cancer cachexia.

Is sarcopenia a disease?

Yes, sarcopenia is formally recognized as an independent muscle disease. The revised European consensus statement (EWGSOP2) explicitly defines sarcopenia as a muscle disease, or muscle failure, rooted in adverse muscle changes that accrue across a lifetime. Sarcopenia is also recognized in formal medical coding systems, carrying its own dedicated ICD-10-CM clinical diagnostic code, M62.84, which is housed in the chapter covering diseases of the musculoskeletal system and connective tissue. This formal coding establishes sarcopenia as a distinct diagnostic entity.

What is the difference between cachexia and malnutrition?

Malnutrition is evaluated by GLIM criteria combining phenotypic and etiologic criteria, whereas cachexia is a complex metabolic syndrome associated with underlying illness. Under the global GLIM criteria, diagnosing malnutrition requires at least one phenotypic criterion (such as non-volitional weight loss, low BMI, or reduced muscle mass) and at least one etiologic criterion (such as reduced food intake or disease inflammation). While cancer cachexia consensus frameworks note that muscle loss cannot be fully reversed by conventional nutrition, GLIM notes the overlap among malnutrition, cachexia, and sarcopenia remains unsettled.

Does cachexia only happen with cancer?

No, cachexia occurs across many chronic illnesses. The general consensus definition published by Evans 2008 defines cachexia as a complex metabolic syndrome associated with underlying illness in general, not solely malignancy. Within oncology specifically, Baracos 2018 notes that cancer cachexia is especially frequent in cancers of the pancreas, oesophagus, stomach, lung, liver, and bowel, which collectively account for half of all global cancer deaths.

Can you have sarcopenia and cachexia at the same time?

Yes, sarcopenia and cachexia can occur simultaneously in the same patient. In the cancer cachexia diagnostic framework published by Fearon 2011, pre-existing sarcopenia is recognized as an explicit risk factor that lowers the diagnostic weight loss threshold. While individuals with normal body mass require greater than 5 percent weight loss for a cancer cachexia diagnosis, individuals who already have sarcopenia or a BMI under 20 kg/m2 meet the criterion with weight loss greater than 2 percent.

Who diagnoses sarcopenia and cachexia?

Both conditions must be formally diagnosed by a licensed medical clinician through physical assessment and diagnostic testing. Sarcopenia is diagnosed by a clinician using functional tests of muscle strength, confirmed by measures of muscle quantity and quality. Cachexia is evaluated and diagnosed by a clinician investigating the underlying illness and documenting involuntary weight loss.

Is sarcopenia only a condition of older age?

No, sarcopenia can develop earlier in life even though it is most common among older adults. The EWGSOP2 revised consensus statement notes that while sarcopenia is common among adults of older age, it can also occur earlier in life.

Related